Background
Clarissa has a strong background in both academic and industry biomedical research environments. She is passionate about translational research and innovative biotechnology that can improve the lives of patients and shape the future of healthcare.
She completed her PhD at The University of Melbourne in 2021, during which she investigated disease progression in malignant glioma and response to treatment as part of the Brain Cancer Invasion Group. Following this, she worked as a lead R&D scientist at a publicly traded biotechnology company to support the company’s pre-clinical drug development pipelines across a range of disease settings, including cancer and infectious disease.
Qualifications
- 2021: PhD, The University of Melbourne, Australia
- 2016: BSc (Hons), The University of Melbourne, Australia
Positions
- 2023-current: Senior Research Officer, Burnet Institute, Victoria, Australia.
- 2022-2023: Senior Research Scientist, Exopharm Ltd, Victoria, Australia.
- 2021-2022: Research Scientist, Exopharm Ltd, Victoria, Australia.
Burnet publications
View 1 moreStellabody: A novel hexamer‐promoting mutation for improved IgG potency
Immunological Reviews
Clarissa A. Whitehead et al
Small extracellular vesicles promote invadopodia activity in glioblastoma cells in a therapy-dependent manner
Cellular Oncology
Clarissa A. Whitehead
Extracellular Vesicles Secreted by Glioma Stem Cells Are Involved in Radiation Resistance and Glioma Progression
International Journal of Molecular Sciences
Clarissa A. Whitehead